Early-Phase Trials Explore Transplant Tolerance in Kidney Care

Early-phase clinical trials are underway to evaluate cellular therapies aimed at improving transplant tolerance in kidney care. Long-term limitations imposed by current immunosuppression options after kidney transplantation have led investigators to evaluate the potential of cellular therapies, with clinicians citing long-term efficacy, pill burden, and graft survival as crucial issues.

While consistent immunosuppression is essential to prevent graft rejection, investigators are exploring immune tolerance strategies designed to retrain the immune system to accept transplanted organs without recognizing them as foreign, while preserving normal immune function. The goal ranges from getting someone entirely off of immunosuppression to reducing the need for drug-based immunosuppression to a low dose of a single agent, described as drug minimization.

Several early-phase clinical trials are currently underway, including a phase 1b study evaluating hematopoietic stem cell transplantation combined with regulatory T-cell therapy in living donor kidney transplant recipients, as well as a randomized phase 2 trial assessing whether patients can be safely transitioned to single-agent immunosuppression. Additional investigational approaches are exploring novel induction strategies using modified donor immune cells.

Across these studies, investigators are closely monitoring immunologic markers to better understand how tolerance may be achieved in practice. This includes assessing donor-specific hyporesponsiveness over time and combining these findings with biomarkers of immune quiescence. Investigators say they want to show evidence of immune regulation that supports reducing immunosuppression, noting that more than 95% of patients require multiple drugs today, so achieving monotherapy would be a major advance.

Reducing exposure to multi-drug regimens may also help mitigate long-term toxicity and potentially improve graft durability. Investigators have said that with current drug-based immunosuppression, the best that can be achieved with a living donor transplant is around 20 years, meaning younger patients may need at least two or three transplants during their lifetime. For some investigators, the long-term goal is to move closer to a model in which a single transplant can last a patient’s lifetime.

While these strategies remain investigational, they reflect ongoing efforts to address persistent limitations in transplant care and improve long-term outcomes for patients. Their adoption could require a shift in how transplant care is delivered toward increasingly personalized approaches.